← All trials
NCT06318481
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 15, 2024
- Primary completion
- Nov 15, 2024
- Completion date
- Dec 15, 2024
- First posted
- Mar 19, 2024
- Last posted
- Mar 19, 2024
- Enrollment
- 2200
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of PakistanLead sponsor
- Government of PakistanSponsor investigator
- PharmEvo Pvt LtdCollaborator
- Government of PakistanOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.